Search

Displaying results 2811 - 2820 of 10000 in total
  1. Drug

    Ritlecitinib

    go.drugbank.com/drugs/DB14924
    ApprovedInvestigational

    In June 2023, it was approved by the FDA for the treatment of severe alopecia areata in adults and adolescents 12 years and older.[L47092,L47127] It was further approved by the EMA in September 2023. … [L48181] Ritlecitinib is administered orally and is the first member of its class.

  2. Drug

    Varespladib methyl

    go.drugbank.com/drugs/DB05737
    Investigational

    Studies showed that Varespladib methyl treatment resulted in significant positive changes on lipoproteins and inflammation.

  3. Drug

    CRx-119

    go.drugbank.com/drugs/DB05688
    Experimental

    CRx-119 is a novel synergistic combination drug candidate discovered using the CombinatoRx combination High Throughput Screening (cHTS(TM)) technology with potential therapeutic use in a broad range of … CRx-119 is a combination of a low dose of the steroid prednisolone, 3mg, and amoxapine.

  4. Drug

    Fluticasone furoate

    go.drugbank.com/drugs/DB08906
    ApprovedInvestigational

    Fluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications[FDA Label][F4364]. Fluticasone furoate was first approved in 2007[L5965].

  5. Drug

    Idoxuridine

    go.drugbank.com/drugs/DB00249
    ApprovedWithdrawn

    An analog of deoxyuridine that inhibits viral DNA synthesis. The drug is used as an antiviral agent.

  6. Drug

    Inaxaplin

    go.drugbank.com/drugs/DB21521
    Investigational

    Inaxaplin is under investigation in clinical trial NCT06794996 (Phase 2b Open-label Study of Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease). … Inaxaplin is a small molecule drug.

  7. Drug

    Alglucosidase alfa

    go.drugbank.com/drugs/DB01272
    ApprovedInvestigational

    It is used for the treatment of Pompe disease (GAA deficiency) in infants and pediatric patients. … It is encoded by the most predominant of nine observed haplotypes of this gene. Aglucosidase alfa is produced by recombinant DNA technology in a Chinese hamster ovary cell line.

    Categories: Glycogen Storage Disease Type II
  8. Drug

    Oxazepam

    go.drugbank.com/drugs/DB00842
    Approved

    Oxazepam is an intermediate-acting, 3-hydroxybenzodiazepine used in the treatment of alcohol withdrawal and anxiety disorders. … [A203516] It is an active metabolite of both [diazepam] and [temazepam][A39486] and undergoes very little biotransformation following absorption, making it unlikely to participate in pharmacokinetic interactions

  9. Drug

    Ademetionine

    go.drugbank.com/drugs/DB00118
    ApprovedInvestigationalNutraceutical

    Physiologic methyl radical donor involved in enzymatic transmethylation reactions and present in all living organisms. … It possesses anti-inflammatory activity and has been used in treatment of chronic liver disease. (From Merck, 11th ed)

    Mixtures: HEPASELAMİN AMİNOASİT IV İNFÜZYON ÇÖZELTİSİ 500 ML SETLİ ŞİŞE, HEPASELAMİN AMİNOASİT IV İNFÜZYON ÇÖZELTİSİ 500 ML SETSİZ ŞİŞE
  10. Drug

    Triheptanoin

    go.drugbank.com/drugs/DB11677
    ApprovedInvestigational

    Triheptanoin is a source of heptanoate fatty acids, which can be metabolized without the enzymes of long chain fatty acid oxidation. … [A214812,A214817] Complications in lc-FAOD patients are reduced from approximately 60% to approximately 10% with the addition of triheptanoin.